SCYNEXIS (SCYX)
(Delayed Data from NSDQ)
$0.73 USD
+0.02 (3.24%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $0.73 0.00 (-0.27%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SCYX 0.73 +0.02(3.24%)
Will SCYX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SCYX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for SCYX
SCYNEXIS Faces Nasdaq Delisting Notice for Stock Price
SCYNEXIS: Positive Developments and Financial Stability Justify Buy Rating
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study | SCYX Stock News
Scynexis resumes patient dosing in Phase 3 MARIO study
SCYNEXIS: Buy Rating Affirmed Amid Strategic Advancements and Promising Antifungal Innovations